Cediranib
Diffuse Midline Glioma, H3 K27M-Mutant
National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
14 Active assets in the Diffuse Midline Glioma, H3 K27M-Mutant cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FULVESTRANT Nationwide Children's Hospital | Phase 2 | B |
Letrozole Nationwide Children's Hospital | Phase 2 | B |
Ribociclib Nationwide Children's Hospital | Phase 2 | B |
Zoladex Nationwide Children's Hospital | Phase 2 | B |
LEUPROLIDE Nationwide Children's Hospital | Phase 2 | B |
View all 15 →
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →